Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

计划入组 24 人 · 首次发布于 2021 年 6 月 7 日

Multicentric Database for KRAS Mutant Pancreatic Cancer

计划入组 1,000 人 · 首次发布于 2026 年 4 月 30 日

Lapatinib Plus Trametinib in KRAS Mutant NSCLC

计划入组 35 人 · 首次发布于 2014 年 9 月 3 日

Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)

Mutant KRAS Inhibitors (solid tumor)

Mutant KRAS G12V-specific TCR tranduced autologous T cell therapy (Changhai Hospital of Shanghai)

BIOTRONIK CRC, INC.

United States

Investigaciones Endocrinologicas de Crc S.A.

Costa Rica

Aprea Therapeutics

United States

Resminostat Shows Promise in Advanced Cancers: Clinical Updates and Biomarker Identification

Breakthrough in Colorectal Cancer Drug Discovery: Novel Nano-Delivery Systems and Precision Therapy Targets Identified

FDA Grants Fast Track Designation to Kestrel's Oral Pan-KRAS Inhibitor KST-6051 for KRAS-Mutant Solid Tumors